Ascendis Pharma A/S is a biopharmaceutical company that applies its TransCon technology platform to develop therapies for endocrinology rare diseases and oncology. The company markets YORVIPATH (palopegteriparatide) for hypoparathyroidism and SKYTROFA (lonapegsomatropin) for growth hormone deficiency. Its pipeline includes TransCon CNP (navepegritide) for achondroplasia and oncology candidates such as TransCon TLR7/8 Agonist and TransCon IL-2 b/g. Ascendis Pharma serves patients in the United States, the European Union, Japan, and Greater China. The company collaborates with Teijin Limited for Japan and VISEN Pharmaceuticals for Greater China. Founded in 2007, the company was formerly known as Ascendis Pharma ApS.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage ascendispharma.com
Sector Healthcare IR page investors.ascendispharma.com
Tags
endocrinology, rare diseases, hypoparathyroidism, growth hormone deficiency, achondroplasia, oncology, transcon technology, long-acting peptides, immunotherapy, YORVIPATH, palopegteriparatide, SKYTROFA, lonapegsomatropin, TransCon CNP, navepegritide, TransCon TLR7/8 Agonist, TransCon IL-2 b/g, onvapegleukin alfa, Teijin Limited, VISEN Pharmaceuticals, Complex Biosystems GmbH
Press page —

Metrics

Valuation  
Market cap $ 17.522B
Market cap (USD) $ 17.522B
P/E 18.10
PEG —
P/BV 10.63
P/S 22.14
P/OCF 295.85
P/FCF 351.12
Dividend yield —
Turnover / mcap —
Returns  
ROE 140.1%
ROI -32.2%
ROIC -14.4%
Profit margin -31.7%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 25.2%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 126
Quality score -5.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 720.132M 363.641M 266.718M 51.174M 7.778M 6.953M 13.375M 10.581M 1.53M 4.606M 8.118M 13.983M 20.408M
Net profit -228.034M -378.084M -481.447M -583.194M -383.577M -418.955M -218.016M -130.097M -123.897M -68.505M -32.936M -9.672M 4.073M
Free cash flow 45.412M -307.624M -469.803M -510.188M -441.353M -291.408M -181.095M -141.45M -96.04M -60.851M -44.505M -18.808M 5.115M

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (EUR) 287,000 — — — — — — — — —
↳ YoY growth -73.0%
Cash and deposits (EUR) 180M — — — — — — — — —
Intangible assets (EUR) 3.5M — — — — — — — — —
Cash flow detail
Operating cash flow (EUR) -60.2M — — — — — — — — —
Purchases of property, plant and equipment (EUR) -672,000 — — — — — — — — —
Change in receivables (cash effect) (EUR) -777,000 — — — — — — — — —
Income taxes paid (cash effect) (EUR) -558,000 — — — — — — — — —
Operating cash flow before change in receivables (EUR) -59.4M — — — — — — — — —
Free cash flow (OCF - PPE - intangibles) (EUR) -60.9M — — — — — — — — —
Income detail
Research and development expense (EUR) 66M 99.6M 140M 192M 261M 296M 380M 413M 307M 304M
↳ 5y CAGR +54.3% +61.6% +57.6% +45.1% +35.0% +30.7% +24.1% +9.9% +3.1%
Reported Mar 22, 2017 Mar 28, 2018 Apr 3, 2019 Apr 3, 2020 Mar 10, 2021 Mar 2, 2022 Feb 16, 2023 Feb 7, 2024 Feb 12, 2025 Feb 11, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

– Q3 2026 product revenue of €366 million (+89% Y/Y), comprising €291 million for

YORVIPATH®, €59 million for SKYTROFA®, and €16 million for YUVIWEL®

– Received positive CHMP and COMP opinions recommending EU marketing authorization

and maintenance of orphan medicinal product designation for TransCon® CNP

– Final EC decision for TransCon CNP expected in Q4 2026; first EU launch planned in

Germany in Q1 2027

– Presented Week 52 sentinel cohort data in infants with achondroplasia aged 0 to

<2 years showing TransCon CNP stabilized or improved foramen magnum stenosis, and

increased linear growth; topline pivotal data expected Q3 2027

– Conference call today at 8:00 a.m. ET

COPENHAGEN, Denmark, November 12, 2026 (GLOBE NEWSWIRE) Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

“By always putting patients first, Ascendis has delivered three consecutive approved rare endocrine therapies that are the foundation of our transformation into a leading global biopharmaceutical company,” said Jan Mikkelsen, President and Chief Executive Officer of Ascendis Pharma.

Ascendis Pharma A/S — Report of foreign private issuer (Form 6-K) Bull 5 Bear 0 Clinical/regulatory

On November 6, 2026, the Company announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending maintenance of orphan medicinal product designation for once-weekly TransCon CNP (navepegritide) as a treatment for achondroplasia in children. The designation would provide Ascendis benefits that include 10 years of orphan market exclusivity upon final adoption of the COMP opinion by the European Commission (EC). The opinion follows the EMA’s Committee for Medicinal Products for Human Use (CHMP) positive opinion recommending marketing authorization for once-weekly TransCon CNP in the European Union for the treatment of achondroplasia in children two years of age and older whose epiphyses are not closed. The final EC decision on Ascendis Pharma’s Marketing Authorisation Application (MAA) is expected during Q4 2026. If authorized by the EC, Ascendis expects its first EU launch of TransCon CNP under the brand name YUVIWEL® to be in Germany during Q1 2027. This report contains forward-looking statements that involve substantial risks and uncertainties.

Prompts

Ascendis Pharma A/S (ticker ASND), listed in United States.

ETFs Holding Ascendis Pharma A/S

ETF Weight in ETF Shares Market value As of
MEDI 16.90% 27,953 $ 7.465M Nov 12, 2026
AFOS 4.02% 40,724 $ 11.04M Nov 18, 2026
AADR 3.49% 4,198 $ 1.138M Nov 17, 2026
FDG 2.72% 43,376 $ 11.41M Aug 31, 2026
TCAF 2.52% 997,972 $ 271.179M Nov 17, 2026
TMED 1.60% 1,382 $ 368.607K Jun 30, 2026
ILDR 1.22% 14,286 $ 3.882M Nov 16, 2026
TCAL 1.14% 13,851 $ 3.764M Nov 17, 2026
FFOG 1.12% 13,117 $ 3.499M Jun 30, 2026
MSSM 0.89% 24,013 $ 6.316M Aug 31, 2026
TMSL 0.35% 35,217 $ 9.393M Jun 30, 2026
ESIM 0.29% 216 $ 52.685K Jul 31, 2026
SXQG 0.27% 606 $ 161.844K Nov 12, 2026
MSLC 0.25% 38,090 $ 10.019M Aug 31, 2026
VFMO 0.09% 6,536 $ 1.719M Aug 31, 2026
BDVL 0.08% 4,909 $ 1.334M Nov 16, 2026
IALT 0.08% 23,046 $ 6.262M Nov 16, 2026
AVUQ 0.03% 431 $ 117.116K Nov 16, 2026
AVLC 0.01% 404 $ 109.779K Nov 16, 2026